US Patent

US8791270 — Bendamustine pharmaceutical compositions

Method of Use · Assigned to Cephalon LLC · Expires 2026-01-12 · 0y expired

Vulnerability score 53/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use.

USPTO Abstract

The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.

Drugs covered by this patent

bendamustine-hydrochloride (BENDAMUSTINE HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1542`	—	bendamustine-hydrochloride
`U-1542`	—	bendamustine-hydrochloride
`U-1790`	—	bendamustine-hydrochloride
`U-1971`	—	bendamustine-hydrochloride
`U-1542`	—	bendamustine-hydrochloride
`U-1542`	—	bendamustine-hydrochloride

Patent Metadata

Patent number: US8791270
Jurisdiction: US
Classification: Method of Use
Expires: 2026-01-12
Drug substance claim: No
Drug product claim: Yes
Assignee: Cephalon LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.